Palvella Therapeutics Statistics
Total Valuation
PVLA has a market cap or net worth of $590.81 million. The enterprise value is $534.89 million.
Important Dates
The last earnings date was Thursday, August 14, 2025, before market open.
Earnings Date | Aug 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
PVLA has 11.06 million shares outstanding. The number of shares has increased by 19.89% in one year.
Current Share Class | 11.06M |
Shares Outstanding | 11.06M |
Shares Change (YoY) | +19.89% |
Shares Change (QoQ) | +0.35% |
Owned by Insiders (%) | 17.94% |
Owned by Institutions (%) | 39.47% |
Float | 6.38M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 12.37 |
P/TBV Ratio | 12.37 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.67, with a Debt / Equity ratio of 0.30.
Current Ratio | 7.67 |
Quick Ratio | 7.53 |
Debt / Equity | 0.30 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -5.20 |
Financial Efficiency
Return on equity (ROE) is -151.15% and return on invested capital (ROIC) is -46.16%.
Return on Equity (ROE) | -151.15% |
Return on Assets (ROA) | -37.25% |
Return on Invested Capital (ROIC) | -46.16% |
Return on Capital Employed (ROCE) | -41.40% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.00M |
Employee Count | 14 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Dividends & Yields
PVLA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -19.89% |
Shareholder Yield | -19.89% |
Earnings Yield | -4.74% |
FCF Yield | n/a |
Analyst Forecast
The average price target for PVLA is $56.64, which is 6.03% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $56.64 |
Price Target Difference | 6.03% |
Analyst Consensus | Strong Buy |
Analyst Count | 11 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |